메뉴 건너뛰기




Volumn 21, Issue 9, 2004, Pages 583-595

Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; TIROFIBAN;

EID: 4043159863     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421090-00003     Document Type: Review
Times cited : (1)

References (55)
  • 1
    • 0344622276 scopus 로고    scopus 로고
    • Bethesda (MD): US Dept of Health and Human Services, Mar
    • National Heart, Lung, and Blood Institute. Fact book: fiscal year 1995. Bethesda (MD): US Dept of Health and Human Services, 1996 Mar: 30-52
    • (1996) Fact Book: Fiscal Year 1995 , pp. 30-52
  • 2
    • 0001340395 scopus 로고    scopus 로고
    • Dyslipidemia and other risk factors for coronary artery disease
    • Braunwald E, editor. Philadelphia (PA): WB Saunders
    • Farmer JA, Gotto Jr AM. Dyslipidemia and other risk factors for coronary artery disease. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. 5th ed. Philadelphia (PA): WB Saunders, 1997: 1126-60
    • (1997) Heart Disease: A Textbook of Cardiovascular Medicine. 5th Ed. , pp. 1126-1160
    • Farmer, J.A.1    Gotto Jr., A.M.2
  • 3
    • 0018412417 scopus 로고
    • Cholesterol in the prediction of atherosclerotic disease: New perspectives based on the Framingham study
    • KanneL WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham study. Ann Intern Med 1979; 90 (1): 85-91
    • (1979) Ann Intern Med , vol.90 , Issue.1 , pp. 85-91
    • Kannel, W.B.1    Castelli, W.P.2    Gordon, T.3
  • 4
    • 0037180771 scopus 로고    scopus 로고
    • Inflammation in atherosclerosis
    • Libby P. Inflammation in atherosclerosis. Nature 2002; 420 (6917): 868-74
    • (2002) Nature , vol.420 , Issue.6917 , pp. 868-874
    • Libby, P.1
  • 5
    • 0033552883 scopus 로고    scopus 로고
    • Atherosclerosis: An inflammatory disease
    • Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340 (2): 15-26
    • (1999) N Engl J Med , vol.340 , Issue.2 , pp. 15-26
    • Ross, R.1
  • 6
    • 0029054734 scopus 로고
    • Molecular bases of the acute coronary syndromes
    • Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91 (11): 2844-50
    • (1995) Circulation , vol.91 , Issue.11 , pp. 2844-2850
    • Libby, P.1
  • 7
    • 0036734558 scopus 로고    scopus 로고
    • Effect of early statin therapy after acute coronary syndromes: A concise review of the recent data
    • Bybee KA, Wright RS, Kopecky SL. Effect of early statin therapy after acute coronary syndromes: a concise review of the recent data. Cardiol Rev 2002; 10 (5): 301-5
    • (2002) Cardiol Rev , vol.10 , Issue.5 , pp. 301-305
    • Bybee, K.A.1    Wright, R.S.2    Kopecky, S.L.3
  • 8
    • 0032572043 scopus 로고    scopus 로고
    • Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
    • Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50
    • (1998) JAMA , vol.279 , pp. 1643-1650
    • Rosenson, R.S.1    Tangney, C.C.2
  • 9
    • 0030499777 scopus 로고    scopus 로고
    • Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points
    • Kinlay S, Selwyn AP, Delagrange D, et al. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol 1996; 7: 389-97
    • (1996) Curr Opin Lipidol , vol.7 , pp. 389-397
    • Kinlay, S.1    Selwyn, A.P.2    Delagrange, D.3
  • 10
    • 0035572718 scopus 로고    scopus 로고
    • Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
    • Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-9
    • (2001) Arterioscler Thromb Vasc Biol , vol.21 , pp. 1712-1719
    • Takemoto, M.1    Liao, J.K.2
  • 11
    • 0026695499 scopus 로고
    • Lovastatin alters blood rheology in primary hyperlipoproteinemia: Dependence on lipoprotein(a)?
    • Koenig W, Hehr R, Ditschuneit HH, et al. Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein(a)? J Clin Pharmacol 1992; 32: 539-45
    • (1992) J Clin Pharmacol , vol.32 , pp. 539-545
    • Koenig, W.1    Hehr, R.2    Ditschuneit, H.H.3
  • 12
    • 0025878734 scopus 로고
    • Lovastatin therapy in hypercholesterolemia: Effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology
    • Beigel Y, Fuchs J, Snir M, et al. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol 1991; 31: 512-7
    • (1991) J Clin Pharmacol , vol.31 , pp. 512-517
    • Beigel, Y.1    Fuchs, J.2    Snir, M.3
  • 13
    • 0028866519 scopus 로고
    • Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
    • Lacoste L, Lam JY, Hung J, et al. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-7
    • (1995) Circulation , vol.92 , pp. 3172-3177
    • Lacoste, L.1    Lam, J.Y.2    Hung, J.3
  • 14
    • 0033587667 scopus 로고    scopus 로고
    • Long-term effects of pravastatin on plasma concentration of C-reactive protein
    • The Cholesterol and Recurrent Events (CARE) Investigators
    • Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100 (3): 230-5
    • (1999) Circulation , vol.100 , Issue.3 , pp. 230-235
    • Ridker, P.M.1    Rifai, N.2    Pfeffer, M.A.3
  • 15
    • 0035806626 scopus 로고    scopus 로고
    • Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
    • Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70
    • (2001) JAMA , vol.286 , pp. 64-70
    • Albert, M.A.1    Danielson, E.2    Rifai, N.3
  • 16
    • 0033386090 scopus 로고    scopus 로고
    • Inflammation markers and coronary heart disease
    • Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol 1999; 10: 435-41
    • (1999) Curr Opin Lipidol , vol.10 , pp. 435-441
    • Tracy, R.P.1
  • 17
    • 0037032291 scopus 로고    scopus 로고
    • Multicentric inflammation in epicardial coronary arteries of patients dying of acute myocardial infarction
    • Spagnoli LG, Bonanno E, Mauriello A, et al. Multicentric inflammation in epicardial coronary arteries of patients dying of acute myocardial infarction. J Am Coll Cardiol 2002; 40 (9): 1579-88
    • (2002) J Am Coll Cardiol , vol.40 , Issue.9 , pp. 1579-1588
    • Spagnoli, L.G.1    Bonanno, E.2    Mauriello, A.3
  • 18
    • 0027987849 scopus 로고
    • Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
    • Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
    • (1994) Lancet , vol.344 , pp. 1383-1389
  • 19
    • 0034601425 scopus 로고    scopus 로고
    • Impact of pravastatin therapy on the risk of stroke: Results from the LIPID study
    • White HD, Simes RJ, Anderson NE, et al. Impact of pravastatin therapy on the risk of stroke: results from the LIPID study. N Engl J Med 2000; 343: 317-26
    • (2000) N Engl J Med , vol.343 , pp. 317-326
    • White, H.D.1    Simes, R.J.2    Anderson, N.E.3
  • 20
    • 0342981862 scopus 로고    scopus 로고
    • The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
    • Cholesterol and Recurrent Events Trial Investigators
    • Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001-9
    • (1996) N Engl J Med , vol.335 , pp. 1001-1009
    • Sacks, F.M.1    Pfeffer, M.A.2    Moye, L.A.3
  • 21
    • 0001328313 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study: Randomized placebo-controlled trial of cho-lesterol lowering with simvastatin in 20,536 high-risk individuals
    • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study: randomized placebo-controlled trial of cho-lesterol lowering with simvastatin in 20,536 high-risk individuals. Lancet 2002; 360: 7-22
    • (2002) Lancet , vol.360 , pp. 7-22
  • 22
    • 0032572086 scopus 로고    scopus 로고
    • Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
    • Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279 (20): 1615-22
    • (1998) JAMA , vol.279 , Issue.20 , pp. 1615-1622
    • Downs, J.R.1    Clearfield, M.2    Weis, S.3
  • 23
    • 0037420492 scopus 로고    scopus 로고
    • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
    • ASCOT investigators
    • Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. ASCOT investigators. Lancet 2003; 361 (9364): 1149-58
    • (2003) Lancet , vol.361 , Issue.9364 , pp. 1149-1158
    • Sever, P.S.1    Dahlof, B.2    Poulter, N.R.3
  • 24
    • 0034901024 scopus 로고    scopus 로고
    • The A-to-Z trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy
    • Blazing MA, De Lemos JA, Dyke CK, et al. The A-to-Z trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001; 142 (2): 211-7
    • (2001) Am Heart J , vol.142 , Issue.2 , pp. 211-217
    • Blazing, M.A.1    De Lemos, J.A.2    Dyke, C.K.3
  • 25
    • 0035941512 scopus 로고    scopus 로고
    • Early statin treatment following acute myocardial infarction and 1-year survival
    • Swedish Register of Cardiac Intensive Care (RIKS-HIA)
    • Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. Swedish Register of Cardiac Intensive Care (RIKS-HIA). JAMA 2001; 285: 430-6
    • (2001) JAMA , vol.285 , pp. 430-436
    • Stenestrand, U.1    Wallentin, L.2
  • 26
    • 0034669445 scopus 로고    scopus 로고
    • Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease
    • Horne BD, Muhlestein JB, Carlquist JF, et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000; 36 (6): 1774-80
    • (2000) J Am Coll Cardiol , vol.36 , Issue.6 , pp. 1774-1780
    • Horne, B.D.1    Muhlestein, J.B.2    Carlquist, J.F.3
  • 27
    • 0035820313 scopus 로고    scopus 로고
    • Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study
    • Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357 (9262): 1063-8
    • (2001) Lancet , vol.357 , Issue.9262 , pp. 1063-1068
    • Aronow, H.D.1    Topol, E.J.2    Roe, M.T.3
  • 28
    • 0000031247 scopus 로고    scopus 로고
    • Role of statins in patients with acute coronary syndromes
    • Hamm CW, Heeschen C, Boehm M, et al. Role of statins in patients with acute coronary syndromes. Circulation 2000; 102 Suppl. 2: II-435
    • (2000) Circulation , vol.102 , Issue.2 SUPPL.
    • Hamm, C.W.1    Heeschen, C.2    Boehm, M.3
  • 29
    • 0035869144 scopus 로고    scopus 로고
    • Effect of concomitant or very early statin administration on in-hospital mortality and re-infarction rates in patients with acute myocardial infarction
    • Bybee KA, Wright RS, Williams B, et al. Effect of concomitant or very early statin administration on in-hospital mortality and re-infarction rates in patients with acute myocardial infarction. Am J Cardiol 2001; 87: 771-4
    • (2001) Am J Cardiol , vol.87 , pp. 771-774
    • Bybee, K.A.1    Wright, R.S.2    Williams, B.3
  • 30
    • 0003203279 scopus 로고    scopus 로고
    • Differential benefit from early treatment with a statin agent after non-ST elevation myocardial infarction compared with ST elevation myocardial infarction
    • Bybee KA, Wright RS, Williams B. Differential benefit from early treatment with a statin agent after non-ST elevation myocardial infarction compared with ST elevation myocardial infarction. Circulation 2000; 102 Suppl. 2: II-614
    • (2000) Circulation , vol.102 , Issue.2 SUPPL.
    • Bybee, K.A.1    Wright, R.S.2    Williams, B.3
  • 31
    • 0000031246 scopus 로고    scopus 로고
    • Early statin use in acute myocardial infarction is associated with a reduced hospital mortality: Results of the Mitra-2
    • Schiele R, Gitt AK, Heer T, et al. Early statin use in acute myocardial infarction is associated with a reduced hospital mortality: results of the Mitra-2. Circulation 2000; 102 Suppl. 2: II-435
    • (2000) Circulation , vol.102 , Issue.2 SUPPL.
    • Schiele, R.1    Gitt, A.K.2    Heer, T.3
  • 32
    • 0000031251 scopus 로고    scopus 로고
    • Initiation of statin therapy immediately after stent implantation: Profound benefit in patients with acute coronary syndromes
    • Walter DH, Fichtlscherer S, Britten MB, et al. Initiation of statin therapy immediately after stent implantation: profound benefit in patients with acute coronary syndromes [abstract]. Circulation 2000; 102 Suppl. 2: II-435
    • (2000) Circulation , vol.102 , Issue.2 SUPPL.
    • Walter, D.H.1    Fichtlscherer, S.2    Britten, M.B.3
  • 33
    • 0001673086 scopus 로고    scopus 로고
    • Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower postdischarge 1-year mortality
    • Giugliano RP, Antman EM, Thompson SL, et al. Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower postdischarge 1-year mortality [abstract]. J Am Coll Cardiol 2001; 37 Suppl. A: 316A
    • (2001) J Am Coll Cardiol , vol.37 , Issue.SUPPL. A
    • Giugliano, R.P.1    Antman, E.M.2    Thompson, S.L.3
  • 34
    • 0001276528 scopus 로고    scopus 로고
    • Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: Observations from OPUS-TIMI 16
    • Cannon CP, McCabe CH, Bentley J, et al. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS-TIMI 16 [abstract]. J Am Coll Cardiol 2001; 37 (A): 334A
    • (2001) J Am Coll Cardiol , vol.37 , Issue.A
    • Cannon, C.P.1    McCabe, C.H.2    Bentley, J.3
  • 35
    • 0037134826 scopus 로고    scopus 로고
    • Early statin initiation and outcomes in patients with acute coronary syndromes
    • SYMPHONY and 2nd SYMPHONY Investigators
    • Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. SYMPHONY and 2nd SYMPHONY Investigators. JAMA 2002; 287: 3087-95
    • (2002) JAMA , vol.287 , pp. 3087-3095
    • Newby, L.K.1    Kristinsson, A.2    Bhapkar, M.V.3
  • 36
    • 0000777968 scopus 로고    scopus 로고
    • The short-term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction
    • Kayikcioglu M, Turkoglu C, Kultursay H, et al. The short-term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction [abstract]. Circulation 1999; 100 Suppl. 1: I-303
    • (1999) Circulation , vol.100 , Issue.1 SUPPL.
    • Kayikcioglu, M.1    Turkoglu, C.2    Kultursay, H.3
  • 37
    • 0035804846 scopus 로고    scopus 로고
    • Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes: The MIRACL study: A randomised controlled trial
    • Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes: The MIRACL study: a randomised controlled trial. JAMA 2001; 285: 1711-8
    • (2001) JAMA , vol.285 , pp. 1711-1718
    • Schwartz, G.G.1    Olsson, A.G.2    Ezekowitz, M.D.3
  • 38
    • 0034672571 scopus 로고    scopus 로고
    • Beneficial effects of pravastatin (+/-cholestyramine/niacin) initiated immediately after a coronary event (the randomised Lipid-Coronary Artery Disease [L-CAD] study)
    • Arntz HR, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin (+/-cholestyramine/niacin) initiated immediately after a coronary event (the randomised Lipid-Coronary Artery Disease [L-CAD] study). Am J Cardiol 2000; 86: 1293-8
    • (2000) Am J Cardiol , vol.86 , pp. 1293-1298
    • Arntz, H.R.1    Agrawal, R.2    Wunderlich, W.3
  • 39
    • 0037177167 scopus 로고    scopus 로고
    • Withdrawal of statins increases event rates in patients with acute coronary syndromes
    • Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators
    • Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Circulation 2002; 105: 1446-52
    • (2002) Circulation , vol.105 , pp. 1446-1452
    • Heeschen, C.1    Hamm, C.W.2    Laufs, U.3
  • 40
    • 0033621148 scopus 로고    scopus 로고
    • 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
    • Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100(9): 1016-30
    • (1999) Circulation , vol.100 , Issue.9 , pp. 1016-1030
    • Ryan, T.J.1    Antman, E.M.2    Brooks, N.H.3
  • 41
    • 0029074028 scopus 로고
    • Quality of care for Medicare patients with acute myocardial infarction: A four-state pilot study from the Cooperative Cardiovascular Project
    • Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction: a four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995; 273: 1509-14
    • (1995) JAMA , vol.273 , pp. 1509-1514
    • Ellerbeck, E.F.1    Jencks, S.F.2    Radford, M.J.3
  • 42
    • 0033135086 scopus 로고    scopus 로고
    • Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease
    • Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83: 1303-7
    • (1999) Am J Cardiol , vol.83 , pp. 1303-1307
    • Sueta, C.A.1    Chowdhury, M.2    Boccuzzi, S.J.3
  • 43
    • 0032168473 scopus 로고    scopus 로고
    • Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines
    • Frolkis JP, Zyzanski SJ, Schwartz JM, et al. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation 1998; 98: 851-5
    • (1998) Circulation , vol.98 , pp. 851-855
    • Frolkis, J.P.1    Zyzanski, S.J.2    Schwartz, J.M.3
  • 44
    • 0034645936 scopus 로고    scopus 로고
    • Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada
    • Miller M, Byington R, Hunninghake D, et al. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Arch Intern Med 2000; 160: 343-7
    • (2000) Arch Intern Med , vol.160 , pp. 343-347
    • Miller, M.1    Byington, R.2    Hunninghake, D.3
  • 45
    • 0035830405 scopus 로고    scopus 로고
    • Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 3
    • National Registry of Myocardial Infarction 3 Participants
    • Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. National Registry of Myocardial Infarction 3 Participants. Circulation 2001; 103: 38-44
    • (2001) Circulation , vol.103 , pp. 38-44
    • Fonarow, G.C.1    French, W.J.2    Parsons, L.S.3
  • 46
    • 0035253035 scopus 로고    scopus 로고
    • Usefulness of in-hospital prescription of statin agents after angiographie diagnosis of coronary artery disease in improving continued compliance and reduced mortality
    • Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographie diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001; 87 (3): 257-61
    • (2001) Am J Cardiol , vol.87 , Issue.3 , pp. 257-261
    • Muhlestein, J.B.1    Horne, B.D.2    Bair, T.L.3
  • 47
    • 0035849549 scopus 로고    scopus 로고
    • In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: The time is now
    • Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. Circulation 2001; 103 (23): 2768-70
    • (2001) Circulation , vol.103 , Issue.23 , pp. 2768-2770
    • Fonarow, G.C.1    Ballantyne, C.M.2
  • 48
    • 0033807731 scopus 로고    scopus 로고
    • The role of statins in acute coronary syndromes: Managing the unmet need
    • Jackson G. The role of statins in acute coronary syndromes: managing the unmet need. Int J Clin Pract 2000; 54 (7): 445-9
    • (2000) Int J Clin Pract , vol.54 , Issue.7 , pp. 445-449
    • Jackson, G.1
  • 49
    • 0035313265 scopus 로고    scopus 로고
    • Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP)
    • Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001; 87 (7): 819-22
    • (2001) Am J Cardiol , vol.87 , Issue.7 , pp. 819-822
    • Fonarow, G.C.1    Gawlinski, A.2    Moughrabi, S.3
  • 50
    • 0000038376 scopus 로고    scopus 로고
    • An institutional discharge medication program reduces future cardiovascular readmissions and mortality: An analysis of 43,841 patients with coronary artery disease
    • Pearson RR, Horne BD, Allen Maycock CA, et al. An institutional discharge medication program reduces future cardiovascular readmissions and mortality: an analysis of 43,841 patients with coronary artery disease [abstract]. J Am Coll Cardiol 2002; 39 Suppl. A: 452A
    • (2002) J Am Coll Cardiol , vol.39 , Issue.SUPPL. A
    • Pearson, R.R.1    Horne, B.D.2    Allen Maycock, C.A.3
  • 51
    • 0037336697 scopus 로고    scopus 로고
    • Secondary prevention after coronary bypass: The American Heart Association "Get with the Guidelines" program
    • Denton TA, Fonarow GC, LaBresh KA, et al. Secondary prevention after coronary bypass: the American Heart Association "Get with the Guidelines" program. Ann Thorac Surg 2003; 75 (3): 758-60
    • (2003) Ann Thorac Surg , vol.75 , Issue.3 , pp. 758-760
    • Denton, T.A.1    Fonarow, G.C.2    LaBresh, K.A.3
  • 52
    • 0027243348 scopus 로고
    • Summary of the second report of the NCEP expert panel (Adult Treatment Panel II)
    • Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the NCEP expert panel (Adult Treatment Panel II). JAMA 1993; 269: 3015-23
    • (1993) JAMA , vol.269 , pp. 3015-3023
  • 53
    • 4043122242 scopus 로고    scopus 로고
    • Implementing approved guidelines in heart disease: Can hospital discharge medication rates be improved?
    • Lappe DL, Kralick-Goldberg S, French TK, et al. Implementing approved guidelines in heart disease: can hospital discharge medication rates be improved? [abstract]. J Card Fail 2000; 6 Suppl. B: 76
    • (2000) J Card Fail , vol.6 , Issue.SUPPL. B , pp. 76
    • Lappe, D.L.1    Kralick-Goldberg, S.2    French, T.K.3
  • 54
    • 0037420492 scopus 로고    scopus 로고
    • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial
    • ASCOT investigators
    • Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. ASCOT investigators. Lancet 2003; 361 (9364): 1149-58
    • (2003) Lancet , vol.361 , Issue.9364 , pp. 1149-1158
    • Sever, P.S.1    Dahlof, B.2    Poulter, N.R.3
  • 55
    • 0037178569 scopus 로고    scopus 로고
    • Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial
    • Lescol Intervention Prevention Study (LIPS) Investigators
    • Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. Lescol Intervention Prevention Study (LIPS) Investigators. JAMA 2002; 287 (24): 3215-22
    • (2002) JAMA , vol.287 , Issue.24 , pp. 3215-3222
    • Serruys, P.W.1    De Feyter, P.2    Macaya, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.